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Abstract
Purpose This study examines endocrine therapy (ET) non-initiation, non-adherence, and duration by age, race, temporal 
trend for South Carolina Medicaid-enrolled women diagnosed with estrogen receptor-positive breast cancer between 2000 
and 2014 (N = 3830).
Methods Age, race, relative risk, and median duration of ET use were compared. Temporal trends in ET non-initiation, 
non-adherence, and duration were observed using linear and logistic regression models, controlling for age and race.
Results Fifty-three percent of women in the sample did not initiate ET, with highest non-initiation rates among African 
Americans and survivors under age 50. Of those who did initiate ET, 42% were non-adherent with a median ET usage dura-
tion of 37 months. Twenty-one percent of initiators continued taking ET for 5 years or more. There was no change in the 
odds of ET non-initiation from 2000 to 2004 (OR 1.02, p = 0.67). The odds of ET non-initiation decreased from 2005 to 
2009 (OR 0.81, p < 0.001) but then increased from 2010 to 2014 (OR 1.08, p = 0.002). There was no change in the odds of 
ET non-adherence from 2000 to 2006 (OR 1.02, p = 0.53), but from 2007 to 2012, the odds of ET non-adherence decreased 
each year (OR 0.93, p = 0.02). The average ET usage duration was increasing from 2000 to 2006 (β = 2.74, p < 0.001) but 
decreasing from 2006 to 2012 (β = − 1.46, p < 0.001).
Conclusions This study provides a realistic picture of the challenges associated with ET usage among South Carolina Medic-
aid breast cancer patients. It particularly highlights small improvements over time in ET usage rates, indicating more oppor-
tunities for improvement in ET initiation, adherence, and duration among younger women of lower socio-economic status.
Keywords Breast cancer · Survivorship · Endocrine therapy · Tamoxifen · Aromatase inhibitors
Introduction
With advances in breast cancer screening and treatment, the 
population of female breast cancer survivors in the United 
States continues to grow and was estimated at over 3.5 mil-
lion as of January 2016 [1]. This population is expected to 
total over 4.5 million by 2026 [1]. An important issue for 
female breast cancer survivors is reducing the risk of cancer 
recurrence. The risk of cancer recurrence can be influenced 
by many factors, including the original cancer and the initial 
treatment.
Endocrine therapy (ET) has been used for decades as the 
primary means of reducing the risk of breast cancer recur-
rence and improving disease-free survival in women with 
estrogen receptor-positive Stage 0-III disease [2]. However, 
non-initiation, non-adherence, and discontinuation rates 
remain high [3, 4]. Numerous cross-sectional studies have 
been published highlighting subgroups of women experienc-
ing the highest rates of ET non-initiation, non-adherence, 
or discontinuation in certain populations, which have often 
included women younger than age 50 or older than age 70, 
of African American race, and/or of economically disadvan-
taged populations [5–11].
Even though there has been greater attention given to ET 
in oncology literature and practice [12, 13], a gap persists 
in the literature regarding how ET usage rates have changed 
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over time. There is an impetus to particularly explore longi-
tudinal patterns among populations that are known to expe-
rience special challenges related to cancer care, especially 
younger and economically disadvantaged women [6, 8, 9, 
14]. The purpose of this study is to describe ET non-initia-
tion, non-adherence, and duration by age, race, and temporal 
trend for South Carolina Medicaid-enrolled women who had 
estrogen receptor-positive breast cancer diagnosed between 
2000 and 2014.
Methods
Data source
South Carolina Central Cancer Registry incidence data 
from 2000 to 2014 were used to identify the study sample 
and then linked with South Carolina Medicaid prescription 
claims and administrative data from 2000 to 2016 [15]. The 
data were linked by South Carolina Department of Revenue 
and Fiscal Affairs using probabilistic match by patient first 
name, last name, Social Security number, and date of birth. 
Data was de-identified prior to release to the researchers. 
Clemson University (IRB2017 133) and South Carolina 
Department of Health and Environmental Control Institu-
tional Review Boards approved the study.
Sample
This retrospective cohort study included South Carolina (SC) 
women ages 18–64 at diagnosis with Stage 0–III or unstaged 
estrogen receptor-positive breast cancer diagnosed between 
2000 and 2014 (N = 34,791). Breast cancer survivors who 
had SEER summary stage 7 cancer (N = 1531), who did not 
have estrogen receptor-positive cancer (N = 5183), who had 
prior cancer diagnoses (N = 3016), or whose cancer was 
identified through autopsy or death certificate (N = 72) were 
excluded. After linking with SC Medicaid prescription data, 
breast cancer survivors who did not meet Medicaid eligibil-
ity inclusion criteria (i.e., no prescription data; N = 18,762 or 
dually enrolled in Medicare; N = 2397) were also excluded. 
Those who were dually enrolled in Medicare were excluded 
because Medicare prescription claims were not available 
and therefore, ET usage could not be reliably tracked. After 
exclusions, there were 3830 breast cancer survivors included 
in this study. (Fig. 1).
Definition of non‑initiation, non‑adherence, 
and duration of ET usage
ET was defined as Tamoxifen/Nolvadex or one of the follow-
ing aromatase inhibitors: Anastrozole/Arimidex, Letrozole/
Femara, or Exemestane/Aromasin, which were identified 
using National Drug Codes from the Medicaid prescription 
claims. Non-initiation was defined as not having any Medic-
aid prescription claims in the entire study period (from 2000 
to 2016). The non-initiation rate was calculated by dividing 
the number of women who were ET non-initiators by the 
total number of eligible women (N = 3830). Non-adherence 
was defined as an ET medication possession ratio of less 
than 80%, meaning that the pill supply covered less than 
80% of the days from the first ET prescription dispense 
date through the last [16]. Duration of ET usage was cal-
culated as the number of months between the first and last 
Females diagnosed with breast cancer between ages 18-64 
during 2000-2014 residing in South Carolina, identified by 
SC Central Cancer Registry (N=34,791) 
Not Medicaid eligible since 2000 (N=18,762) 
SEER Summary Stage 7 - Distant (N=1,531) 
Had prior cancer diagnosis (N=3,016) 
Cancer identified through autopsy or death 
certificate (N=72) 
Not estrogen receptor-positive (N=5,183) 
Dually enrolled in Medicare (N=2,397)  
Total sample included in study (N=3,830)  
Fig. 1  Cohort selection criteria
761Breast Cancer Research and Treatment (2018) 171:759–765 
1 3
ET prescription dispense date. The proportion of women 
taking ET for at least 5 years was calculated by dividing 
the total number of women taking ET for at least 5 years by 
the total number of women initiating ET. Non-adherence 
and duration were calculated using the date dispensed and 
days supplied variables from the South Carolina Medicaid 
pharmacy claims file.
Statistical analysis
Demographic characteristics were compared between ET 
initiators and non-initiators using Chi square tests. Relative 
risk was calculated for ET non-initiation for each of the age/
race subgroups, with white/age ≥ 50 years as the reference 
group.
ET non-adherence and usage duration analyses were con-
ducted among women who had filed at least one ET pre-
scription claim through South Carolina Medicaid and who 
were diagnosed between 2000 and 2012 (N = 1366). Women 
diagnosed in 2013 and 2014 were excluded due to the short-
ened follow-up time since prescription records were only 
available through 2016. Chi square (χ2) tests were used to 
test for a difference in non-adherence rates among age/race 
subgroups (i.e., White/age < 50 years, African American/
age < 50 years, White/age ≥ 50 years, African American/
age ≥ 50 years). Relative risk of ET non-adherence was 
calculated for each of the age/race subgroups, with White/
age ≥ 50 years as the reference group. Kruskal Wallis tests 
were used to test for a difference in median duration of ET 
usage by age/race subgroups as previously defined.
We also examined temporal trends in endocrine therapy 
(ET) non-initiation, non-adherence, and duration. Tempo-
ral trend was measured by calendar year of breast cancer 
diagnosis. The objective was to study participants in groups 
by year of breast cancer diagnosis since much of the infor-
mation and motivation a woman receives for taking ET in 
the long-term is provided in the initial conversation with a 
provider when the patient receives the first ET prescription.
We used logistic regression to model whether an indi-
vidual initiated ET or not. We also used logistic regression 
to model whether an individual was adherent to ET or not. 
We used ordinary least squares linear regression to estimate 
an individual’s ET usage duration in months. In each of the 
three models, we controlled for the covariates age (contin-
uous variable centered at the mean) and race (0 = White, 
1 = African American).
The data was first examined visually and descriptive sta-
tistics were calculated. The data did not meet the assump-
tions for linearity for any of the three outcomes, so non-
linear time trend models were chosen. Non-initiation rates 
resembled a cubic pattern, so the time period was divided 
into three sub-periods to capture different trends occur-
ring during these three sub-periods. Non-adherence and 
duration seemed to generally increase until the year 2006 
and decrease thereafter, so time was divided into two sub-
periods for these analyses.
To allow for nonlinear changes in ET non-initiation 
over time, we used a linear spline with knots at 2004 and 
2009. For non-initiation, we divided time into the peri-
ods 2000–2004, 2005–2009, and 2010–2014. To allow for 
changes in ET non-adherence and duration observed before 
and after 2006, we used a linear spline with a knot at 2006. 
For non-adherence and duration, we observed changes in the 
periods 2000–2006 and 2007–2012. Wald tests were used 
to determine whether the coefficients for the different time 
periods were equivalent. Adjusted trends were examined by 
generating predicted probabilities of ET non-initiation and 
non-adherence as well as average duration from the devel-
oped models. Stata 14.2 was used for all analyses.
Results
Initiation
There were 3830 Medicaid-eligible women who had estro-
gen receptor-positive breast cancer diagnosed between 2000 
and 2014 who met the inclusion criteria for this analysis. 
Approximately half of these women (53%, N = 2030) did not 
fill an ET prescription as evidenced by Medicaid prescrip-
tion claims.
Demographic characteristics of ET initiators and non-ini-
tiators were examined. (Table 1) The highest non-initiation 
rates were seen in African Americans (55% non-initiation) 
and survivors under age 50 (56% non-initiation). Com-
pared to White women ≥ 50, the relative risks for African 
Americans < 50, White women < 50 and African American 
women ≥ 50 were 1.24 (95% CI 1.14, 1.36), 1.23 (95% CI 
1.12, 1.34), and 1.16 (95% CI 1.05, 1.28), respectively. Non-
initiation rates and risk ratios by age/race subgroups are pre-
sented in Table 2.
Table 1  Demographic characteristics of South Carolina Medicaid 
breast cancer survivor endocrine therapy (ET) initiators and non-initi-
ators, 2000–2014
The statistical differences were tested using χ2 tests
Initiators 
(N = 2030) (%)
Non-initiators 
(N = 1800) (%)
p values
Race (%) 0.025
 White 50 53
 African American 49 45
Age (%) < 0.001
 < 50 years old 40 47
 ≥ 50 years old 60 53
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Non‑adherence
Among all initiators, 42% (N = 755) of survivors were non-
adherent. There was a statistically significant difference 
in the non-adherence rates among the age/race subgroups 
(χ2 = 57.91, df = 3, p < 0.001). African American women 
younger than 50 years old had the highest non-adherence 
rates (55%) and were 1.67 [95% CI (1.43, 1.95)] times as 
likely to be non-adherent to ET compared to the most adher-
ent group (i.e., White women age 50 or older). Risk ratios 
for non-adherence by age/race subgroups are presented in 
Table 3.
Duration
The median duration of ET usage from 2000 to 2012 was 
37 months (range 0–184). Twenty-one percent of survivors 
(N = 288) who initiated ET during 2000–2012 continued 
taking ET for 5 or more years. Five percent (N = 90) only 
filled one ET prescription and did not refill after the first 
prescription. A Kruskal Wallis test showed there was no 
significant difference in median duration of ET usage by age/
race subgroups (χ2 = 1.12, df = 3, p = 0.77).
Temporal trends
The non-initiation rates by year of diagnosis are presented 
in Table 4. We found a significant difference in the ET 
non-initiation trends in the three time periods examined 
(χ2(3) = 126.74, p < 0.001). There was no change in the odds 
Table 2  Endocrine therapy (ET) non-initiation rates (%) and relative 
ratios (95% CI) by age and race subgroups of South Carolina Medic-
aid breast cancer survivors
Race Age
< 50 years ≥ 50 years
Rate
 White 56% 46%
 African American 57% 53%
Relative risk
 White 1.23 (1.12, 1.34) 1.00
 African American 1.24 (1.14, 1.36) 1.16 (1.05, 1.28)
Table 3  Endocrine therapy (ET) non-adherence rates (%) and relative 
ratios (95% CI) by age and race subgroups of South Carolina Medic-
aid Breast cancer survivors
Race Age
< 50 years ≥ 50 years
Rate
 White 45% 33%
 African American 55% 34%
Relative risk
 White 1.36 (1.18, 1.63) 1.00
 African American 1.67 (1.43, 1.95) 1.04 (0.86, 1.27)
Table 4  Endocrine therapy (ET) non-initiation rates among South Carolina Medicaid breast cancer survivors by year of diagnosis, 2000–2014
Year of breast 
cancer diagnosis
White/age < 50 years 
(N = 1093) %
African American/
age < 50 years (N = 1034) 
%
White/age ≥ 50 years 
(N = 872) %
African American/
age ≥ 50 years (N = 757) %
All Women in 
Sample (N = 3830), 
%
2000 66.2 69.2 63.4 61.5 65.3
2001 75.0 69.4 40.0 65.9 64.0
2002 69.2 68.1 61.0 73.2 68.2
2003 73.1 63.0 73.5 66.7 69.2
2004 64.1 71.1 64.9 74.4 67.3
2005 53.2 64.7 60.0 57.1 58.3
2006 52.5 50.0 43.5 74.3 53.4
2007 50.0 49.2 41.9 56.8 49.0
2008 58.7 53.7 52.5 50.0 53.4
2009 47.1 43.2 28.3 38.9 40.7
2010 41.4 46.2 32.8 38.9 40.3
2011 45.3 50.7 31.1 48.1 42.6
2012 55.4 52.5 41.9 47.3 49.5
2013 49.5 54.5 42.0 37.9 46.0
2014 58.3 54.3 46.0 39.5 50.1
2000–2014 57.3 57.3 48.2 55.4 54.5
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of ET non-initiation from 2000 to 2004 (OR 1.02, p = 0.67). 
The odds of ET non-initiation decreased from 2005 to 2009 
(OR 0.81, p < 0.001) but then increased from 2010 to 2014 
(OR 1.08, p = 0.002).
The non-adherence rates and median duration of ET 
usage by year of breast cancer diagnosis are presented in 
Table 5. Results showed that there was a significant differ-
ence in the ET non-adherence trends before and after 2006 
(χ2(2) = 7.01, p = 0.03). There was no change in the odds of 
ET non-adherence from 2000 to 2006 (OR 1.02, p = 0.53), 
but from 2007 to 2012, the odds of ET non-adherence 
decreased each year (OR 0.93, p = 0.02).
There was also a significant difference in the ET usage 
duration trends before and after 2006 (F(2,1361) = 15.51, 
p < 0.001). The average ET usage duration was increasing 
from 2000 to 2006 (β = 2.74, p < 0.001) but decreasing from 
2007 to 2012 (β = − 1.46, p < 0.001).
Figure 2 presents the adjusted average probabilities of ET 
non-initiation and non-adherence by year of breast cancer 
diagnosis as well as the adjusted average ET usage duration 
by year of breast cancer diagnosis.
Conclusion
This is the first study to use longitudinal data to examine 
trends in ET non-initiation, non-adherence, and duration 
among South Carolina Medicaid-enrolled women. Our 
Table 5  Demographics and endocrine therapy (ET) usage non-adherence and duration patterns in South Carolina Medicaid breast cancer survi-
vors by year of diagnosis, 2000–2014
a Survivors diagnosed in 2013 and 2014 could only be followed for 48 and 36 months, respectively
b Sample included all female Medicaid recipients ages 18–64 at diagnosis with Stage 0–III or unstaged estrogen receptor-positive breast cancer 
diagnosed between 2000 and 2014 who filled at least one ET prescription. Survivors with prior cancer diagnoses, who were dually enrolled in 
Medicare, or whose cancer was identified through autopsy or death certificate were excluded
Year of 
 diagnosisa
Total no. in 
 sampleb
No. White, 
age < 50 years
No. African Ameri-
can, age < 50 years
No. White, 
age ≥ 50 years
No. African Ameri-
can, age ≥ 50 years
Percent non-
adherent (N)
Median duration of 
ET (range),  monthsb
2000 74 22 16 15 20 46% (34) 20.5 (0–184)
2001 77 14 22 24 15 47% (36) 22 (0–142)
2002 77 20 29 16 11 47% (36) 30 (0–167)
2003 74 18 27 13 16 50% (37) 23.5 (0–112)
2004 54 14 13 13 10 44%(24) 21.5 (0–147)
2005 78 29 18 14 15 50% (39) 34 (0–123)
2006 88 28 23 26 9 50% (44) 49.5 (0–119)
2007 103 27 33 25 16 47% (48) 46 (0–111)
2008 96 26 25 19 23 47% (45) 39 (0–90)
2009 162 45 42 38 33 42% (68) 46.5 (0–138)
2010 173 51 42 43 33 42% (72) 41 (0–79)
2011 179 47 36 62 28 34% (61) 45 (0–137)
2012 164 41 38 54 29 38% (62) 39 (0–142)
Fig. 2  Adjusted trends in South 
Carolina Medicaid breast cancer 
survivors’ endocrine therapy 
non-initiation, non-adherence, 
and duration by year of breast 
cancer diagnosis
0
10
20
30
40
50
60
70
80
2000 2002 2004 2006 2008 2010 2012 2014
Adjusted Average Probability of ET Non-Initiation
Adjusted Average Probability of ET Non-Adherence
Adjusted Average Duration of ET Usage
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findings point to several opportunities for further investi-
gation and possible intervention. First, 53% of the Medic-
aid enrollees included in the analysis never initiated treat-
ment. This is of concern for multiple reasons. Secondly, 
when examining the subgroups for possible intervention 
to increase ET adherence, women under 50 years of age, 
and especially African American women under age 50, 
demand particular attention. Thirdly, the odds of ET non-
initiation was increasing from 2010 to 2014 and the aver-
age duration of ET usage was decreasing from 2007 to 
2012.
There was, however, a significant decline in the odds of 
ET non-adherence from 2007 to 2012, and the odds of ET 
non-initiation had decreased previously in the period from 
2005 to 2009 with average duration increasing from 2000 
to 2006. These positive findings are encouraging given the 
recent attention touting the benefits of ET adherence for 
women [6]. Because the study spans more than a decade, 
this data offers one of the first long-term assessments of 
these challenges. The opportunity is to build on the modest 
positive improvements seen earlier in the past decade.
Those who initiated ET had a median ET usage duration 
of 37 months (range 0–184), with 21% of initiators continu-
ing ET for 5 years or more. Given ASCO’s recommenda-
tions since 2014 to increase ET usage to up to 10 years in 
some subgroups and multiple trials showing disease-free 
survival benefits for those who take ET for 5–10 years [12, 
13, 17–19], it is alarming that only one-fifth of initiators 
continued for 5 years or more and that the temporal trends 
showed negative results for the most recent periods con-
cerning improvement in individual level ET initiation and 
duration.
We found that women under age 50 were less likely to be 
adherent to ET. These findings are consistent with the litera-
ture on ET usage [8], which suggests that younger women 
have unique considerations in their ET decision-making 
framework, including fertility [20] and reluctance to believe 
ET was a necessary part of their breast cancer treatment 
[21]. These explanatory factors are not fully understood and 
warrant further research [22].
Some important limitations accompany this analysis. 
First, we assumed that if a person was Medicaid-eligible 
and did not have a Medicaid pharmacy claim for ET, she 
did not take ET, as there was no other way to document ET 
received through other payment sources. Medicaid recipients 
do not typically have secondary payment sources other than 
self-pay, so it is not anticipated that significant missed data 
resulted from this limitation. Second, we assumed that if a 
person filled a prescription, then she took those pills. There 
was no way to account for whether the women actually took 
the medication. Furthermore, our findings were based on 
data from the South Carolina Medicaid population and may 
not be generalizable to other populations.
While promising that rates of non-initiation showed 
slight yet significant decreasing trends and duration showed 
a slight yet significant increasing trend, these results sound a 
call for greater improvements in ET usage rates among pop-
ulations of low socioeconomic status treatment so that early 
real-time interventions to improve adherence can be intro-
duced and examined. More research is needed to decipher 
potential factors influencing slight improvements seen since 
2000 in order to capitalize on these efforts to further reduce 
rates of non-initiation and non-adherence and increase dura-
tion in the future. Moreover, longitudinal analyses among 
women with private insurance or Medicare are warranted 
to compare changes in ET usage rates over time among 
these populations. Additional analyses should also consider 
grouping participants by the year corresponding to the mid-
dle or end of an individual’s ET duration period, where this 
study chose to group participants by year of breast cancer 
diagnosis.
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